This is the first report regarding the enhancive role of the DPYSL2/PKM2 axis in bladder cancer progression, providing the DPYSL2/PKM2 axis as a promising therapeutic target in bladder cancer treatment. This evidence concerns the gene DPYSL2 and urinary bladder cancer.